Related Experiment Video
Updated: Dec 5, 2025
A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
Published on: May 21, 2010
Generation of Common Marmoset Model Lines of Spinocerebellar Ataxia Type 3
Ikuo Tomioka1,2, Yoshitaka Nagai3,4, Kazuhiko Seki2
1Department of Biomedical Engineering, Shinshu University, Nagano, Japan.
Abstract:
Animal models are indispensable tools in the development of innovative treatments for rare and incurable diseases. To date, there is almost no effective treatment for neurodegenerative diseases, and animal models that properly simulate human disease pathologies are eagerly anticipated to identify disease biomarkers and develop therapeutic methods and agents. Among experimental animals, non-human primates are the most suitable animal models for the study of neurodegenerative diseases with human-specific higher brain dysfunction and late-onset and slowly progressing symptoms. With the rapid development of novel therapies such as oligonucleotide therapeutics and genome editing technologies, non-human primate models for neurodegenerative diseases will be essential for preclinical studies and active interventional trials. In a previous publication, we reported the generation of the first transgenic marmoset model of spinocerebellar ataxia type 3 and successful obtainment of subsequent generations with stable disease onset. Moreover, we generated transgenic marmosets in which the transgene was controlled by the tetracycline-inducible gene expression system. In this mini-review, we summarize the research on our marmoset model of spinocerebellar ataxia type 3.
Insights
Researchers developed a transgenic marmoset model for spinocerebellar ataxia type 3, a rare neurodegenerative disease. This model is crucial for advancing treatments and understanding human-specific brain dysfunction.
Area of Science:
- Neuroscience
- Genetics
- Primate Models
Background:
- Neurodegenerative diseases lack effective treatments, necessitating advanced animal models.
- Non-human primates are ideal for studying human-specific neurodegenerative conditions due to shared brain complexity and disease progression.
- Novel therapies require robust preclinical models for development and testing.
Purpose of the Study:
- To review the development and application of a transgenic marmoset model for spinocerebellar ataxia type 3 (SCA3).
- To highlight the utility of this primate model for studying human-specific neurodegenerative diseases.
- To discuss the potential of this model in preclinical studies for novel therapeutics.
Main Methods:
- Generation of transgenic marmosets carrying the SCA3 gene.
- Establishment of stable breeding lines with consistent disease onset.
- Implementation of a tetracycline-inducible gene expression system for controlled transgene activity.
Main Results:
- Successful creation of the first transgenic marmoset model of spinocerebellar ataxia type 3.
- Demonstration of stable inheritance and disease onset in subsequent generations.
- Development of an inducible system for precise control over disease modeling.
Conclusions:
- The transgenic marmoset model provides a valuable platform for SCA3 research.
- This model is essential for advancing the development of effective treatments for neurodegenerative diseases.
- Inducible non-human primate models are critical for future therapeutic interventions and clinical trials.
